Literature DB >> 28589944

Cerebellar hypoplasia with endosteal sclerosis is a POLR3-related disorder.

Jamal Ghoumid1,2,3, Florence Petit1,2,3, Odile Boute-Benejean1,2, Frédéric Frenois1,2, Maryse Cartigny4, Clémence Vanlerberghe1,2,3, Thomas Smol2,3,5, Roseline Caumes1, Nicolas de Roux6,7,8, Sylvie Manouvrier-Hanu1,2,3.   

Abstract

CHES (cerebellar hypoplasia with endosteal sclerosis) syndrome (OMIM#213002) associates hypomyelination, cerebellar atrophy, hypogonadism and hypodontia. So far, only five patients have been described. The condition is of neonatal onset. Patients have severe psychomotor delay and moderate to severe intellectual disability. Inheritance is assumed to be autosomal recessive due to recurrence in sibs, consanguinity of parents and absence of vertical transmission. CHES syndrome is reminiscent of 4H-leukodystrophy, a recessive-inherited affection due to variations in genes encoding subunits of the RNA polymerase III (POLR3A-POLR3B-POLR1C). POLR3B variants have been identified in one CHES patient. Here we report on a novel CHES patient, carrying compound heterozygous variations in POLR3B. This report confirms affiliation of CHES to POLR3-related disorders and suggests that CHES syndrome represents a severe form of 4H-leukodystrophy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28589944      PMCID: PMC5567146          DOI: 10.1038/ejhg.2017.73

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  14 in total

1.  Rare dental peculiarities associated with the hypomyelinating leukoencephalopathy 4H syndrome/ADDH.

Authors:  Anna Wolff; Martin J Koch; Silke Benzinger; Hubertus van Waes; Nicole I Wolf; Eugen Boltshauser; Hans Ulrich Luder
Journal:  Pediatr Dent       Date:  2010 Sep-Oct       Impact factor: 1.874

2.  What to call a syndrome.

Authors:  Raoul C M Hennekam
Journal:  Am J Med Genet A       Date:  2007-05-15       Impact factor: 2.802

3.  Three human RNA polymerase III-specific subunits form a subcomplex with a selective function in specific transcription initiation.

Authors:  Z Wang; R G Roeder
Journal:  Genes Dev       Date:  1997-05-15       Impact factor: 11.361

4.  Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.

Authors:  Nicole I Wolf; Adeline Vanderver; Rosalina M L van Spaendonk; Raphael Schiffmann; Bernard Brais; Marianna Bugiani; Erik Sistermans; Coriene Catsman-Berrevoets; Johan M Kros; Pedro Soares Pinto; Daniela Pohl; Sandya Tirupathi; Petter Strømme; Ton de Grauw; Sébastien Fribourg; Michelle Demos; Amy Pizzino; Sakkubai Naidu; Kether Guerrero; Marjo S van der Knaap; Geneviève Bernard
Journal:  Neurology       Date:  2014-10-22       Impact factor: 9.910

5.  Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy.

Authors:  Martine Tétreault; Karine Choquet; Simona Orcesi; Davide Tonduti; Umberto Balottin; Martin Teichmann; Sébastien Fribourg; Raphael Schiffmann; Bernard Brais; Adeline Vanderver; Geneviève Bernard
Journal:  Am J Hum Genet       Date:  2011-10-27       Impact factor: 11.025

Review 6.  Cerebellar hypoplasia-endosteal sclerosis: a long term follow-up.

Authors:  Heval M Ozgen; Wouterina C G Overweg-Plandsoen; Janneke Blees-Pelk; Philip P Besselaar; Raoul C M Hennekam
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

7.  Autosomal recessive cerebellar hypoplasia and endosteal sclerosis: a newly recognized syndrome.

Authors:  J Charrow; A K Poznanski; F M Unger; M Robinow
Journal:  Am J Med Genet       Date:  1991-12-15

8.  Diffuse hypomyelination is not obligate for POLR3-related disorders.

Authors:  Roberta La Piana; Ferdy K Cayami; Luan T Tran; Kether Guerrero; Rosalina van Spaendonk; Katrin Õunap; Sander Pajusalu; Tobias Haack; Evangeline Wassmer; Dagmar Timmann; Hanna Mierzewska; Bwee T Poll-Thé; Chirag Patel; Helen Cox; Tahir Atik; Huseyin Onay; Ferda Ozkınay; Adeline Vanderver; Marjo S van der Knaap; Nicole I Wolf; Geneviève Bernard
Journal:  Neurology       Date:  2016-03-30       Impact factor: 9.910

9.  Phenotypic spectrum of POLR3B mutations: isolated hypogonadotropic hypogonadism without neurological or dental anomalies.

Authors:  Mary R Richards; Lacey Plummer; Yee-Ming Chan; Margaret F Lippincott; Richard Quinton; Philip Kumanov; Stephanie B Seminara
Journal:  J Med Genet       Date:  2016-08-10       Impact factor: 6.318

10.  Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III.

Authors:  Isabelle Thiffault; Nicole I Wolf; Diane Forget; Kether Guerrero; Luan T Tran; Karine Choquet; Mathieu Lavallée-Adam; Christian Poitras; Bernard Brais; Grace Yoon; Laszlo Sztriha; Richard I Webster; Dagmar Timmann; Bart P van de Warrenburg; Jürgen Seeger; Alíz Zimmermann; Adrienn Máté; Cyril Goizet; Eva Fung; Marjo S van der Knaap; Sébastien Fribourg; Adeline Vanderver; Cas Simons; Ryan J Taft; John R Yates; Benoit Coulombe; Geneviève Bernard
Journal:  Nat Commun       Date:  2015-07-07       Impact factor: 14.919

View more
  4 in total

1.  Functions of paralogous RNA polymerase III subunits POLR3G and POLR3GL in mouse development.

Authors:  Xiaoling Wang; Alan Gerber; Wei-Yi Chen; Robert G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-23       Impact factor: 11.205

2.  MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass.

Authors:  Ellen Phillips; Naseer Ahmad; Li Sun; James Iben; Christopher J Walkey; Aleksandra Rusin; Tony Yuen; Clifford J Rosen; Ian M Willis; Mone Zaidi; Deborah L Johnson
Journal:  Elife       Date:  2022-05-25       Impact factor: 8.713

Review 3.  RNA Polymerases I and III in development and disease.

Authors:  Kristin En Watt; Julia Macintosh; Geneviève Bernard; Paul A Trainor
Journal:  Semin Cell Dev Biol       Date:  2022-04-11       Impact factor: 7.499

Review 4.  Hypomyelinating leukodystrophies - unravelling myelin biology.

Authors:  Nicole I Wolf; Charles Ffrench-Constant; Marjo S van der Knaap
Journal:  Nat Rev Neurol       Date:  2020-12-15       Impact factor: 42.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.